Jacobs Levy Equity Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-64,425
| Closed | -$238K | – | 1126 |
|
|
2017
Q4 | $238K | Buy |
+64,425
| New | +$264K | ﹤0.01% | 874 |
|
|
2017
Q2 | – | Sell |
-12,400
| Closed | -$51K | – | 1079 |
|
|
2017
Q1 | $51K | Buy |
+12,400
| New | +$52.1K | ﹤0.01% | 897 |
|
|
2016
Q4 | – | Sell |
-19,222
| Closed | -$189K | – | 1122 |
|
|
2016
Q3 | $189K | Sell |
19,222
-24,300
| -56% | -$172K | ﹤0.01% | 919 |
|
|
2016
Q2 | $246K | Sell |
43,522
-23,750
| -35% | -$161K | 0.01% | 948 |
|
|
2016
Q1 | $513K | Buy |
67,272
+56,172
| +506% | +$433K | 0.01% | 722 |
|
|
2015
Q4 | $148K | Hold |
11,100
| – | – | ﹤0.01% | 720 |
|
|
2015
Q3 | $182K | Sell |
11,100
-33,852
| -75% | -$694K | ﹤0.01% | 721 |
|
|
2015
Q2 | $1.01M | Sell |
44,952
-44,543
| -50% | -$705K | 0.02% | 465 |
|
|
2015
Q1 | $875K | Buy |
89,495
+64,033
| +251% | +$628K | 0.01% | 503 |
|
|
2014
Q4 | $290K | Buy |
25,462
+14,894
| +141% | +$162K | 0.01% | 691 |
|
|
2014
Q3 | $122K | Buy |
+10,568
| New | +$161K | ﹤0.01% | 786 |
|
Jacobs Levy Equity Management's CASC Position: Q1 2018 in Review
Jacobs Levy Equity Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 64,425 shares — an estimated $238K sold.
Jacobs Levy Equity Management first reported a position in CASC in Q3 2014 and held it in 11 quarters. The position peaked at $1.01M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Jacobs Levy Equity Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Jacobs Levy Equity Management sold 64,425 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $238K.
- Jacobs Levy Equity Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 11 quarters.
- Jacobs Levy Equity Management's Cascadian Therapeutics, Inc. position peaked at $1.01M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2018, filed 15 May 2018.